Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Phibro Animal Health (PAHC) EBITDA (2016 - 2026)

Phibro Animal Health has reported EBITDA over the past 14 years, most recently at $50.3 million for Q4 2025.

  • For Q4 2025, EBITDA rose 814.35% year-over-year to $50.3 million; the TTM value through Dec 2025 reached $148.1 million, up 291.11%, while the annual FY2025 figure was $110.5 million, 107.19% up from the prior year.
  • EBITDA for Q4 2025 was $50.3 million at Phibro Animal Health, up from $30.5 million in the prior quarter.
  • Over five years, EBITDA peaked at $50.3 million in Q4 2025 and troughed at -$7.0 million in Q4 2024.
  • A 5-year average of $16.7 million and a median of $18.9 million in 2021 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: soared 1521.43% in 2022 and later tumbled 380.12% in 2024.
  • Year by year, EBITDA stood at $10.8 million in 2021, then dropped by 3.47% to $10.5 million in 2022, then crashed by 75.99% to $2.5 million in 2023, then crashed by 380.12% to -$7.0 million in 2024, then soared by 814.35% to $50.3 million in 2025.
  • Business Quant data shows EBITDA for PAHC at $50.3 million in Q4 2025, $30.5 million in Q3 2025, and $33.7 million in Q2 2025.